Clinical Trial Update: Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for seladelpar (MBX-8025) in subjects with primary biliary cholangitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Seladelpar (seladelpar)

Snippet

Sponsor: Gilead Sciences | Conditions: Primary Biliary Cirrhosis | Phase 2 | Status: COMPLETED | Results posted: 2022-07-14